Recursion Pharmaceuticals
-
Artificial Intelligence, BioPharma
Nvidia’s $50M Recursion Investment Starts Alliance to Scale Up in AI Drug Discovery
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
-
Artificial Intelligence, BioPharma
AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions
Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
MedCity Influencers, BioPharma
A Dose of Innovation
As gene sequencing, machine learning, powerful imaging, sensors, gene and cell therapies make their way out of academic labs into everyday healthcare, our approach to healthcare is changing. For the first time, not only can we pinpoint the molecular and genetic causes of disease, but we also have the technologies to access them. On the back of this, prevention and cures are becoming possible. Can we afford them?
-
Artificial Intelligence, BioPharma
Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs
The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.
-
Artificial Intelligence, BioPharma
AI offers promise but faces barriers in drug development
Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.
-
Startups, Artificial Intelligence, BioPharma
Recursion raises $239M in Series D, partners with lead investor Bayer
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker’s molecule library and Recursion’s artificial intelligence-based drug discovery platform.
-
Startups, Artificial Intelligence, BioPharma
AI drug discovery company Recursion Pharmaceuticals raises $121M Series C
Recursion’s technology works by generating millions of cellular images and using AI-based software as a way to analyze the data set and screen potential therapeutic compounds against a variety of diseased cells.
-
Artificial Intelligence, BioPharma
Watson for Drug Discovery may be down, but AI in biopharma isn’t out
Last month, it was reported that IBM would stop selling Watson for Drug Discovery, but executives in the field of biopharma artificial intelligence say the field is still going strong.
-
With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals
In addition to its expansion into bioengineering, the early stage venture capital firm has also shifted its investment strategy to include strategic growth investments.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.